• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Brexit means little for biotech stocks, analyst says

    Brexit means little for biotech stocks, analyst says

  2. Global Small-Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Amgen , Johnson & Johnson - Research and Markets

    Global Small-Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Amgen , Johnson & Johnson - Research and Markets

  3. Why Are Primecap Funds So Sustainable?

    These Gold-rated funds have Morningstar Sustainability Ratings of High despite not explicitly trying to do so.

  4. Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

    Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

  5. CFO Network Members -- WSJ

    CFO Network Members -- WSJ

  6. Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders

    Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders

  7. Global Atherosclerosis Pipeline Report 2016 - Review of 40 Companies & Drug Profiles - Research and Markets

    Global Atherosclerosis Pipeline Report 2016 - Review of 40 Companies & Drug Profiles - Research and Markets

  8. Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update with Compilation of Currently Active R&D Projects - Research and Markets

    Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update with Compilation of Currently Active R&D Projects - Research and Markets

  9. New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

    New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

  10. Amgen Shares Still Look Undervalued

    The firm’s recent pipeline productivity should help stabilize its wide economic moat, writes Morningstar’s Karen Anderson.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.